



Maine Prescription Drug Affordability Board | February 24, 2025 GLP-1 Receptor Agonists: Past, Present, and Future

Benjamin N. Rome, MD, MPH

Assistant Professor of Medicine, Harvard Medical School

Program on Regulation, Therapeutics, and Law (PORTAL) Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women's Hospital



@bnrome in

@benro.me 😽

🛾 brome@bwh.harvard.edu 🔼

Brigham and Women's Hospital Founding Member, Mass General Brigham

Disclosures

- Research funded by grants from:
 - Arnold Ventures
 - The Elevance Public Policy Institute
 - The Greenwall Foundation
 - The National Academy for State Health Policy and 3 state prescription drug affordability boards (CO, OR, WA)
- Consulting for the non-profit Alosa Health (academic detailing)



Outline


- History of GLP-1 agonists
 - Supporting clinical data & FDA approvals
- Treatment cost eligible population
- Coverage of GLP-1 agonists
 - Medicare & Medicaid
 - Other payers
- So what are the options?



2005-2015: Just another diabetes drug?

- First daily injectable GLP1 agonists approved for diabetes based on ability to lower A1c compared to placebo
 - 2005: exenatide (Byetta)
 - 2010: liraglutide (Victoza)
- Mainstay diabetes therapies remained metformin, sulfonylureas, and insulin.

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes






2016-2020: A really good diabetes drug!

- Weekly injectable GLP1s
 - 2014: dulaglutide (Trulicity)
 - 2017: semaglutide (Ozempic)
- Evidence that GLP1 agonists lowered risk of cardioavascular events and death (in patients with diabetes)
 - Jun 2016: LEADER (liraglutide)
 - Sep 2016: SUTAIN-6 (semaglutide)
 - Jun 2019: REWIND (dulaglutide)
- By 2019, GLP1-RAs (and SGLT2 inhibitors) became preferred 2nd line treatments (after metformin) for patients with diabetes and cardiovascular disease.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes


 Steven P. Marso, M.D., Gilbert H. Daniels, M.D., Kirstine Brown-Frandsen, M.D., Peter Kristensen, M.D., E.M.B.A., Johannes F.E. Mann, M.D., Michael A. Nauck, M.D., Steven E. Nissen, M.D., Stuart Pocock, Ph.D., Neil R. Poulter, F.Med.Sci., Lasse S. Ravn, M.D., Ph.D., William M. Steinberg, M.D., Mette Stockner, M.D., Bernard Zinman, M.D., Richard M. Bergenstal, M.D., and John B. Buse, M.D., Ph.D., for the LEADER Steering Committee on behalf of the LEADER Trial Investigators*





2021*-2023: The anti-obesity era

- Even the first diabetes trials of GLP1 agonists demonstrated weight loss.
- FDA approvals for weight loss in patients without diabetes
 - *2014: liraglutide (Saxenda)
 - ~8% body weight loss
 - 2021: semaglutide (Wegovy)
 - ~15% body weight loss
 - 2023: tirzepatide (Zepbound)
 - ~20% body weight




2024-present: More than just weight loss...

• 2024 FDA Approvals

- Semagltuide to reduce cardiovascular risk in patients with obesity + established cardiovascular disease
- Tirzepatide for moderate-tosevere obstructive sleep apnea
 + obesity.

A Primary Cardiovascular Composite End Point





Weeks

Regimen

Estimand


Current FDA approved indications

	Liraglutide	DulagItuide	Semagtlutide	Tirzepatide
Trade Names	Victoza (diabetes), Saxenda)	Trulicity	Ozempic (diabetes), Wegovy	Mounjaro (diabetes), Zepbound
Manufacturer	Novo Nordisk	Eli Lilly	Novo Nordisk	Eli Lilly
Admin Schedule	Daily	Weekly	Weekly	Weekly
Diabetes approvals				
Glycemic control	Х	Х	X	Х
Cardiovascular risk	Х	Х	X	
Kidney disease			X	
Obesity approvals				
Weight management	Х		X	Х
Cardiovascular risk			X	
Sleep apnea				Х



Cost of GLP-1 Receptor Agonists


Diabetes Obesity





9

The problem: High prevalence of obesity



40 states with >30% prevalence of obesity



Coverage in Medicare & Medicaid

Medicaid

- Since 1991, the Medicaid Drug Rebate Program entitles states to receive substantial manufacturer discounts on prescription drugs, but in return must cover essentially all FDA-approved drugs.
- Certain drug classes were exempted from this coverage requirement, including "agents when used for anorexia, weight loss, or weight gain."
- Coverage for anti-obesity medications is optional


Medicare Part D


- When enacted in 2003, Medicare Part D statutorily excluded coverage of the same list of drugs that are optional for coverage in Medicaid.
- Coverage for anti-obesity medications is not allowed



State Medicaid coverage of GLP1s in 2023

Figure 1. Coverage of Antiobesity Medications in Medicaid States With Preferred Drug Lists in 2023^a





GLP-1 RAs for diabetes



Expanding Medicare Coverage

March 2024



TREATMENTS

Medicare plans can now cover Wegovy for patients at risk of heart disease

UPDATED MARCH 22, 2024 · 12:18 PM ET 0

By Yuki Noguchi, Carmel Wroth



November 2024

HEALTH CARE



Weight loss drugs could soon be covered by Medicare and Medicaid

NOVEMBER 26, 2024 · 5:13 PM ET HEARD ON ALL THINGS CONSIDERED

By Sydney Lupkin

"CMS now proposes to reinterpret the statute to permit [Medicare Part D] coverage of anti-obesity medications for the treatment of obesity when such drugs are indicated to reduce excess body weight and maintain weight reduction long-term for individuals with obesity...this reinterpretation would also apply to the Medicaid program. As a result, antiobesity medications...could not be excluded from Medicaid coverage."



Impacts of Expanding Medicare Coverage

OBSERVATIONS: BRIEF RESEARCH REPORTS


- Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention
- 28% of Medicare beneficiaries with obesity/overweight already eligible due to diabetes
- At least **14% newly eligible** based on cardiovascular disease
 - Higher if more liberal definition

By Benedic Ippolito and Joseph F. Levy

Expanding Medicare Coverage Of Anti-Obesity Medicines Could Increase Annual Spending By \$3.1 Billion To \$6.1 Billion

EXHIBIT 4

Percent of qualifying patients with obesity or overweight, as of 2024, who have other conditions for which glucagon-like peptide-1 receptor agonists (GLP-1s) could be approved by 2026 and beyond



Medicare price negotiation

- January 2025: Semaglutide selected for second round of price negotiation under the Inflation Reduction Act
 - Includes both diabetes (Ozempic) and obesity (Wegovy) versions
 - Negotiated price and mandatory Part D coverage will take effect in 2027
- Unclear how this will affect prices & coverage of other GLP1 receptor agonists

Medicare to Negotiate Lower Prices for Weight-Loss Drugs

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.







Other payers also struggling with coverage




MARCH 7, 2024

Statement Regarding GLP-1 Coverage

At the January 25, 2024, State Health Plan Board of Trustees, the board voted to remove GLP-1 and GIP-GLP-1 agonist medications from State Health Plan coverage for the purpose of weight loss effective April 1, 2024. These medications will still be covered for members managing diabetes. Read on for more information. Scroll to the bottom of this page for RFI Responses. "It is estimated that continuing to cover this class of medications for weight loss would result in a premium increase of **\$48.50 per subscriber per month**, doubling the premium for all individual subscribers, even those not taking these medications."



The fundamental dilemma



Highly effective treatments that address a major public health crisis in the US

High cost and large number of eligible patients will lead to substantial increases in health care spending





Some people are paying for GLP agonists out-of-pocket

Direct-to-consumer Pharmacies

Self-pay only	Exclusively through Litey Direct*
Single-Do Supply available	se Vial
Doses: 2.5 mg, 5 mg	
\$ 399 per month for 2.5 mg [†]	*549 per month for 5 mg ^t
Insurance is not accepted, F accepted at checkout. Inject available from our pharmacy nominal fee at checkout.	tion supplies will be

Compounded versions while branded versions were in shortage*

Super Bowl ad for Hims & Hers' weight loss drug sparks backlash

Hims & Hers sells a compounded weight loss medication.

By Jennifer Leong and Katie Kindelan GMA February 11, 2025, 5:20 PM





This photo provided by Hims & Hers shows Hims & Hers 2025 Super Bowl NFL football spot. Hims & Hers via AP

*Shortages officially ended for tirzepatide (Dec 2024) and semaglutide (Feb 2025)



So what are the options for payers?

Not cover the drugs

• Patients who can afford them could pay cash

Cover, but with high cost-sharing

• Concerns about equitable access; not applicable for Medicare (\$2000 cap) or Medicaid

Cover for limited populations

• Focus on those most likely to benefit (e.g., severe obesity or obesity with comorbid conditions)

Other coverage restrictions

- Concurrent or prior behavioral weight management programs
- Trial of less expensive anti-obesity medications (E.g. MassHealth requires phentermine)

Negotiate lower prices (or higher rebates)

• Leverage competition between 2 manufactures (Novo Nordisk & Eli Lilly)



Questions & Discussion

• Thank you!

